CD274 and neoplasm: In 2019, the US Food and Drug Administration (FDA) approved atezolizumab, an anti-PD-L1 antibody, in combination with nanoparticle albumin-bound (nab)-paclitaxel as a first-line therapy targeting the factor sustaining immunosuppression in the tumor environment [22].